Treatment with brepocitinib at 30 and 60 mg daily outperforms placebo at relieving signs and symptoms of psoriatic arthritis (PsA), with a safety ... Treatment with brepocitinib at 30 and…
A new clinical trial shows potential for the drug brepocitinib to treat psoriatic arthritis, reducing symptoms by as much as 20%. A new clinical trial shows potential for the…
THURSDAY, May 18, 2023 (HealthDay News) -- For patients with moderately to severely active psoriatic arthritis, the tyrosine kinase 2/Janus kinase ... THURSDAY, May 18, 2023 (HealthDay News) -- For…
Arthritis & Rheumatology publishes the highest quality basic and clinical research related to the rheumatic diseases, encompassing a wide range of ... Arthritis & Rheumatology publishes the highest quality basic…
Mease, P., et al. (2023) Efficacy and Safety of Tyrosine Kinase 2/Janus Kinase 1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb ... Mease, P., et al. (2023) Efficacy…
A phase IIb randomized clinical trial published in Arthritis & Rheumatology recently generated promising efficacy and safety data for the use of ... A phase IIb randomized clinical trial published…